Canaccord initiated coverage of Veru (VERU) with a Buy rating and $25 price target Veru is positioned as a differentiated biotech in obesity drug development, with lead candidate enobosarm, an oral selective androgen receptor agonist, being evaluated in Phase IIb alongside a GLP-1 receptor agonist to preserve muscle during weight loss, the analyst tells investors in a research note. A second Phase IIb trial is planned for 1Q26, with top-line data expected in 1H28, the firm says.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERU:
- Options Volatility and Implied Earnings Moves Today, December 17, 2025
- Options Volatility and Implied Earnings Moves This Week, December 15 – December 19, 2025
- Is VERU a Buy, Before Earnings?
- Veru Announces Public Offering to Raise $23.4 Million
- Veru prices 1.4M shares at $3.00 in underwritten public offering